García-Callejo FJ, López-Sánchez I, Oishi N, Reboll-Ferrer RM, Sánchez- Jiménez Á, Arribas-Graullera M

Language: Spanish
References: 25
Page: 136-149
PDF size: 300.26 Kb.

ABSTRACT

Objective: To evalute trends about management on anticoagulated outpatients consulting for epistaxis at non-hospitalary otorhinolaryngological attendance, specially on the new non-antivitamin K anticoagulants (NAVK).
Patient and Method: A retrospective, observational, descriptive, transversal study was done from July 2010 and June 2018 in which retrospective data about epidemiologic, clinical and laboratory findings were studied on individuals presenting epistaxis derived from Primary Health needing ENT aid but querying no hospital assistance. We measured the visits/patient ratio and the number of acute crisis of epistaxis on anticoagulated subjects with acenocumarol or new anticoagulants (dabigatran, apixaban and rivaroxaban).
Results: In the study period 513 patients (93 with acenocumarol and 56 with new NAVK anticoagulants) were encountered to be visited 715 times. People under acenocumarol effect decreased significantly following a regression equation y = -9048 x +22,071, with a ratio visit/patient ratio continuously in 1.53-1.55. Among individuals submitted to NAVK anticoagulants, this ratio expressed an increase from 1 to 2.63, and the volume of visits also grew up in a statistically significant link. The clinical severity of epistaxis in the visits of patients with NAVK anticoagulants was significantly higher than in the acenocumarol group as well, for every studied score.
Conclusion: The introduction of NAVK anticoagulants has reduced the amount of patients suffering epistaxis comparing to acenocumarol, but their dates number have raised, needing more procedures to develop on them.

REFERENCES

1. Mateo J. Nuevos anticoagulantes orales y su papel en la práctica clínica. Rev Esp Cardiol Supl 2013;13(C):33-41.

2. Heneghan C, Ward A, Perera R, Bankhead C, Fuller A, Stevens R, et al. Self-monitoring trialist collaboration, self-monitoring of oral anticoagulation: systematic review and meta-analysis of individual patient data. Lancet 2012;379:322-34.

3. Navarro JL, César JM, Fernández MA, Fontcuberta J, Reverter JC, Gol-Freixa J. Morbilidad y mortalidad en pacientes con tratamiento anticoagulante oral. Rev Esp Cardiol 2007;60:1226-32.

4. Diener HC, Easton JD, Hankey GJ, Hart RG. Novel oral anticoagulants in secondary prevention of stroke. Best Pract Res Clin Haematol 2013;26:131-9.

5. Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixabán. Adv Ther 2012;29:491-507.

6. Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, et al. Questions and answers on the use of dabigatrán and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA). Thromb Haemost 2011;106:868-76.

7. Musgrave KM, Powell J. A systematic review of antithrombotic therapy in epistaxis. Rhinol 2016;54:292-391.

8. Katsanis E, Luke KH, Hsu E, Li M, Lillicrap D. Prevalence and significance of mild bleeding disorders in children with recurrent epistaxis. J Pediatr 1988;113:73-6.

9. González-Fernández-Tresguerres F, Álvarez-Sirvent A, Torres-García-Denche J, Fernández-Tresguerres-Hernández- Gil I. Nuevos anticoagulantes orales: repercusión odontológica. Cient Dent 2016;13(2):139-48.

10. Stiefelhagen P. Nasenbluten unter NOAK - was tun? MMW Fortschr Med 2015;157:25.

11. Pinilla Urraca M. Tratamiento de la epistaxis en Atención Primaria. Form Act Pediatr Aten Prim 2014;7:93-100.

12. Escabasse V, Bequignon E, Vérillaud B, Robard L, Michel J, Malard O, et al. Guidelines of the French Society of Otorhinolaryngology (SFORL). Managing epistaxis under coagulation disorder due to antithrombotic therapy. Eur Ann Otorhinolaryngol Head Neck Dis 2017;134:195-9.

13. Bequignon E, Vérillaud B, Robard L, Michel J, Pruliére Escabasse VS, Crampette L, et al. Guidelines of the French Society of Otorhinolaryngology (SFORL). First-line treatment of epistaxis in adults. Eur Ann Otorhinolaryngol Head Neck Dis 2017;134:195-9.

14. Clinkard D, Barbic D. Tranexamic acid for epistaxis –A promising treatment that deserves further study. CJEM 2016;18:72-3.

15. Traboulsi H, Alam E, Hadi U. Changing trends in the management of epistaxis. Int J Otolaryngol 2015. http://dx.doi. org/10.1155/2015/263987

16. Gökdogan O, Akyldiz I, Sayin BY, Okutucu S, Tanato AC, Arslan N. The rate of epistaxis incidence in new-generation anticoagulants and perioperative approach in otorhinolaryngological practices. J Craniofac Surg 2017;28:178-82.

17. Milling TJ, Fromm C, Ganetsky M, Pallin DJ, Cong J, Singer AJ. Management of major bleeding events in patients treated with dabigatrán for nonvalvular atrial fibrillation: a retrospective, multicenter review. Ann Emerg Med 2017;69:531-40.

18. García Callejo FJ, Bécares Martínez C, Calvo González J, Martínez Beneyto MP, Marco Sanz Músculo, Marco Algarra J. Epistaxis y dabigatrán, nuevo anticoagulante oral no antagonista de la vitamina K. Acta Otorrinolaringol Esp 2014;65:346-54.

19. Chen BC, Viny AD, Garlich FM, Basciano P, Howñand MA, Smith SW, et al. Hemorrhagic complications associated with dabigatrán use. Clin Toxicol 2012;50: 854-7.

20. Pahs L, Beavers C, Schuler P. The real-world treatment of hemorrhages associated with dabigatrán and rivaroxabán: a multicenter evaluation. Crit Pathw Cardiol 2015;14:53-61.

21. Romanelli RJ, Nolting L, Dolginsky M, Kym E, Orrico KB. Dabigatrán versus warfarin for atrial fibrillation in real-world clinical practice: A systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes 2016;9:126-34.

22. Bahit MC, Lopes RD, Wojdyla DM, Held C, Hanna M, Vinereanu D, et al. Non-major bleeding with apixabán versus warfarin in patients with atrial fibrillation. Heart 2017;103:623-8.

23. Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, et al. Major bleeding in patients with atrial fibrillation receiving apixabán or warfarin: The ARISTOTLE trial (apixabán for reduction in stroke and other thromboembolic events in atrial fibrillation): Predictors, Characteristics, and clinical outcomes. J Am Coll Cardiol 2014;63:2141-7.

24. Mantha S, Ansell J. Ain indirect comparison of dabigatrán, rivaroxabán and apixabán for atrial fibrillation. Thromb Haemost 2012;108:476-84.

25. Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, et al. Comparison of efficacy and safety of dabigatrán, rivaroxabán and apixabán in patients with atrial fibrillation using network meta-analysis. Int Angiol 2012;31:330-9.